Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Protectin D1 Prevents Bird Flu Infection in Mouse Model

By BiotechDaily International staff writers
Posted on 21 Mar 2013
The omega-3 polyunsaturated fatty acid (PUFA)-derived lipid mediator glycoprotein protectin D1 (PD1) prevents infection by the influenza virus, including the deadly H5N1 strain of bird flu, in a mouse model.

Around 60% of humans known to have been infected with the current Asian strain of bird flu (H5N1) have died from it, and virologists fear that H5N1 may mutate or undergo an antigenic shift into a strain capable of efficient human-to-human transmission.

PD1, which is also known as CD59 complement regulatory protein, is a cell surface glycoprotein that regulates complement-mediated cell lysis and is involved in lymphocyte signal transduction. This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly of this complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation. Viruses such as HIV, human cytomegalovirus, and vaccinia incorporate host cell PD1 into their own viral envelope to prevent lysis by complement. PD1 also plays a role in signal transduction pathways in the activation of T-cells.

Investigators at Akita University (Japan) screened compounds for their ability to inhibit influenza virus replication in human lung tissue. The most active compound they found was PD1. Results published in the March 7, 2013, online edition of the journal Cell revealed that PD1 markedly lessened influenza virus replication via RNA export machinery. Production of PD1 was suppressed during severe influenza, and PD1 levels inversely correlated with the pathogenicity of H5N1 viruses. PD1 treatment improved the survival and pathology of mice with severe influenza infection, even under conditions where known antiviral drugs failed to protect from death.

"Given the potential for future lethal pandemics, effective drugs are needed for the treatment of severe influenza, such as that caused by H5N1 viruses," said senior author Dr. Yumiko Imai, professor of experimental medicine at Akita University. "We have identified a novel therapeutic target for the treatment of severe influenza that is effective under conditions where known antiviral drugs fail to protect from death. Our findings suggest that PD1could serve as a biomarker as well as a much needed antiviral drug for severe and lethal influenza virus infections."

Related Links:

Akita University




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Differences in the structure of a small lung artery (top row) and heart cross section (lower row) of rodents without disease (far left column); with pulmonary hypertension (middle) and a diseased rodent treated with the HDL peptide (right). Note the much narrowed lung artery, and thick walls and larger chamber of the heart in the diseased animal and improvements with 4F peptide treatment (Photo courtesy of UCLA - University of California, Los Angeles).

Apolipoprotein A-1 Mimetic Peptide Reverses Pulmonary Hypertension in Rodent Models

A small peptide that mimics the activity of apolipoprotein A-1 (apo A-1), the main protein component of the high density lipoproteins (HDL), counteracted the effects of oxidized lipids and alleviated symptoms... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.